The Spatial Distribution of LGR5+ Cells Correlates With Gastric Cancer Progression by Simon, Eva et al.
The Spatial Distribution of LGR5











1Institute of Pathology, Christian-Albrechts-University, Kiel, Germany, 2Department of Medicine II, Faculty of Clinical Medicine Mannheim, University of Heidelberg,
Mannheim, Germany
Abstract
In this study we tested the prevalence, histoanatomical distribution and tumour biological significance of the Wnt target
protein and cancer stem cell marker LGR5 in tumours of the human gastrointestinal tract. Differential expression of LGR5
was studied on transcriptional (real-time polymerase chain reaction) and translational level (immunohistochemistry) in
malignant and corresponding non-malignant tissues of 127 patients comprising six different primary tumour sites, i.e.
oesophagus, stomach, liver, pancreas, colon and rectum. The clinico-pathological significance of LGR5 expression was
studied in 100 patients with gastric carcinoma (GC). Non-neoplastic tissue usually harboured only very few scattered LGR5
+
cells. The corresponding carcinomas of the oesophagus, stomach, liver, pancreas, colon and rectum showed significantly
more LGR5
+ cells as well as significantly higher levels of LGR5-mRNA compared with the corresponding non-neoplastic
tissue. Double staining experiments revealed a coexpression of LGR5 with the putative stem cell markers CD44, Musashi-1
and ADAM17. Next we tested the hypothesis that the sequential changes of gastric carcinogenesis, i.e. chronic atrophic
gastritis, intestinal metaplasia and invasive carcinoma, are associated with a reallocation of the LGR5
+ cells. Interestingly, the
spatial distribution of LGR5 changed: in non-neoplastic stomach mucosa, LGR5
+ cells were found predominantly in the
mucous neck region; in intestinal metaplasia LGR5
+ cells were localized at the crypt base, and in GC LGR5
+ cells were
present at the luminal surface, the tumour centre and the invasion front. The expression of LGR5 in the tumour centre and
invasion front of GC correlated significantly with the local tumour growth (T-category) and the nodal spread (N-category).
Furthermore, patients with LGR5
+ GCs had a shorter median survival (28.068.6 months) than patients with LGR5
2 GCs
(54.566.3 months). Our results show that LGR5 is differentially expressed in gastrointestinal cancers and that the spatial
histoanatomical distribution of LGR5
+ cells has to be considered when their tumour biological significance is sought.
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Introduction
Gastrointestinal carcinomas are among the most common
malignancies and are a leading cause of cancer death worldwide
[1,2]. The reasons for the poor prognoses are complex: many
cancers of the gastrointestinal tract are diagnosed in advanced
stages excluding curative treatment, there are no reliable tumour
markers which may allow early diagnosis or screening of high-risk
populations. Treatment options are limited in locally advanced
and metastatic disease, and a significant number of tumours recur
despite initial therapeutic response [3]. A putative explanation of
an ineffective therapy is the presence of cancer stem cells (CSC).
The CSC hypothesis postulates that a tumour is a conglomerate of
heterogeneous cell populations. Only a subpopulation of this
conglomerate maintains the capability of colony formation, and
hence recurrence and metastatic spread. CSCs are more resistant
to chemotherapy, leading to tumour recurrence, progression and
ultimately patient death [4,5]. While the CSC-model is increas-
ingly accepted, identification and confirmation of so called stem
cell markers in native human tissue is difficult and largely missing.
Recently, the leucine-rich, G-protein coupled receptor (GPCR)
and Wnt target gene LGR5 was identified as a novel stem cell
marker of the small intestine, colon and in the hair follicles of mice
[6]. Expression of LGR5 in multiple other organs indicates that it
may represent a global marker of adult stem cells. However, little
is known about its expression in the hepato-gastrointestinal tract of
humans.
In this study we aimed to fill this gap of information and tested
the hypothesis that the cancer stem cell marker LGR5 has
prognostic and tumour biological significance.
Materials and Methods
Subjects
Formalin-fixed and paraffin-embedded malignant and corre-
sponding non-malignant tissue from 127 patients comprising six
anatomical locations of the hepato-gastrointestinal tract (i.e.
oesophagus, stomach, liver, pancreas, colon and rectum) were
retrieved from the archives of the Institutes of Pathology of the
Christian-Albrechts-University Kiel and the Charite ´ University
Hospital Berlin (both Germany). All patients were operated at
either University Hospital Schleswig-Holstein (1997–2009) or
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35486Charite ´ University Hospital Berlin (1995–2008; Table 1). Unfixed,
fresh frozen tissue was available from 105 of these patients with
eight different tumour types, i.e. Barrett’s adenocarcinoma (9
patients) and squamous cell carcinoma (7) of the oesophagus,
intestinal (19) and diffuse (21) type gastric cancer, adenocarcinoma
of the colon (19) and rectum (20), hepatocellular carcinoma (HCC;
4), and cholangiocarcinoma (CC; 6). The patient characteristics
are summarized in Table 1.
An independent series of 487 gastric cancer patients was
retrieved from the archive of the Institute of Pathology of the
Christian-Albrechts-University (Table 2 and Table 3). These
patients had undergone either total or partial gastrectomy for
adenocarcinomas of the stomach or oesophago-gastric junction.
Each resection specimen had undergone histological examination
by trained surgical pathologists. The time of patient death was
obtained from the Epidemiological Cancer Registry of the state
Schleswig-Holstein, Germany. Follow-up data of patients still
alive were retrieved from hospital records and by contacting the
general practitioners.
Ethics Statement
All tissue samples were obtained as part of a diagnostic or
therapeutic surgery carried out after the patient gave written
informed consent. Patients offering samples for the study were
pseudonymized and analyzed anonymously, so no individual-
related data are contained in the database. The study was
approved by the local ethics committee of the University Hospital
in Kiel, Germany (ref. number D 453/10).
Real-time reverse transcriptase polymerase chain
reaction
Total RNA was isolated from cultured cells and cryoconserved
tissues using Ambion’s mirVana miRNA Isolation Kit (Applied
Biosystems, Darmstadt, Germany) followed by a DNase treatment
with Turbo DNA-free kit (Ambion). RNA quality was assessed in a
1.5% agarose gel. For cDNA synthesis, 2 mg of total RNA was
reverse transcribed using Transcriptor First Strand cDNA
Synthesis Kit (Roche Diagnostics, Mannheim, Germany). Gene-
specific primers were synthesized by Biomers.net (Ulm, Germany)
(Table S1). Real-time reverse transcriptase polymerase chain
reaction (Real-time RT-PCR) was carried out using the Light-
CylerH 480 Probes Master (Roche) and the LightCyclerH 480
System (Roche). The comparative Ct values were normalized to
that of three housekeeping genes: Homo sapiens succinate dehydrogenase
complex, subunit A, flavoprotein (Fp) (SDHA), Homo sapiens calpain 2
(CAPN2) and Cyclophilin C (CYCC). No template controls (no cDNA
in PCR) were run for each gene to detect unspecific or genomic
amplification and primer dimerization. All experiments were
performed in duplicates.
Generation and purification of an anti-LGR5-antibody
Polyclonal antisera were generated against the carboxy-terminal
tail of the human LGR5 receptor. Rabbits were immunized with
three different peptides of the identity of SPAYPVTESCHLSS-
VAFVPCL (called Cterm), RSKHPSLMSINSDDVEKQSC
(called 11b), CSITYDLPPSSVPSPAYPVTE (called 12) by
Pineda-abservice (Berlin, Germany). Monospecific IgG was purified
by fast protein liquid chromatography with A ¨KTAprime
TM system
(GE Healthcare, Uppsala, Sweden) using a protein A-column (GE
Healthcare). For all subsequent analyses, i.e. immunofluorescence,
immunocytochemistry, western blot and immunohistochemistry,
the monospecific IgG-fraction was affinity purified against the
immunizing peptides by the Pineda-abservice. In dot blot analyses
and immunohistochemical investigations, the monospecific IgG
anti-LGR5-11b antibody displayed high affinity along with strong
and specific immunostaining. Therefore, this antibody was used
throughout this study. The reactivity and specificity of the
monospecific antibody was characterized by western blot; immu-
nofluorescence and immunocytochemical assays.
Plasmid construct
Expression construct for LGR5 was generated by amplifying the
whole coding sequence of human LGR5 (NM_003667.2) by PCR
(Table S1). To facilitate subcloning of the amplified fragment into
the expression vector pcDNA3.1(2), the forward primer contained
a NheI restriction site adaptor and the reverse primer contained a
BamHI site and a c-Myc tag to verify successful transfection. PCR
fragments and the pcDNA3.1(2) expression vector were digested
Table 1. Patient characteristics of the hepato-gastrointestinal cohort.




(range) m:w p value* Total
Mean age
(range) m:w LGR5
+ n( % )
IRS
(mean) LGR5




Oesophagus AC 9 63 (51–74) 4:5 0.007 8 64 (51–78) 5:3 5 (63) 2.83 2 (25) 0.75 0.140
Oesophagus SCC 7 64 (48–73) 4:3 0.503 6 66 (48–73) 4:2 3 (50) 2.00 2 (33) 1.00 0.317
Stomach intestinal 19 69 (54–85) 8:5 0.006 13 67 (54–85) 8:5 12 (92) 3.54 9 (69) 2.00 0.020
Stomach diffuse 21 68 (43–82) 9:10 0.013 19 69 (55–82) 9:10 17 (90) 3.00 6 (32) 0.95 0.003
HCC 4 62 (43–73) 8:8 0.545 16 59 (17–82) 8:8 8 (50) 2.19 5 (31) 0.88 0.028
CC 6 63 (46–77) 4:4 0.022 8 64 (46–77) 4:4 6 (75) 2.38 0 (0) 0.00 0.026
Pancreas 0 n.d. n.d. n.d. 17 62 (50–78) 7:10 17 (100) 4.29 12 (71) 2.47 0.013
Colon 19 70 (45–85) 9:11 ,0.001 20 74 (45–89) 9:11 18 (90) 3.80 12 (60) 1.65 ,0.001
Rectum 20 64 (40–84) 10:10 0.002 20 64 (40–84) 10:10 17 (85) 3.90 17 (85) 2.35 0.011
P values were calculated with a paired two-sided t-test (*) or the Wilcoxon test ({). Immunohistochemistry data depict the overall expression of LGR5 in malignant (TU)
and corresponding non-malignant (NT) tissue. Immunoreactivity scores (IRS) were calculated for tumour cells. n.d.=not detected. AC=adenocarcinoma.
SCC=squamous cell carcinoma. HCC=hepatocellular carcinoma. CC=cholangiocarcinoma. m=man. w=woman. LGR5
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Patients, n (%) 100 49 (49) 51 (51) 61 (61) 39 (39) 63 (63) 37 (37) 39 (39) 61 (61)
Age (mean ± SD) 69611.8 7069.7 6969.9 71611.8 69611.3 7269.4 68610.4 71610.8
Age, n (%)
p value 0.836* 0.293* 0.200* 0.032*
,71 47 23 (49) 24 (51) 31 (66) 16 (34) 33 (70) 14 (30) 23 (49) 24 (51)
$71 47 21 (45) 26 (55) 25 (53) 22 (47) 26 (55) 21 (45) 12 (26) 35 (74)
Gender, n (%)
p value 0.655* 0.063* 0.648* 0.645*
Male 73 37 (51) 36 (49) 49 (67) 24 (33) 47 (64) 26 (36) 30 (41) 43 (59)
Female 27 12 (44) 15 (56) 12 (44) 15 (56) 16 (59) 11 (41) 9 (33) 18 (67)
Localization, n (%)
p value 1.000* 1.000* 0.369* 0.129*
Proximal 32 16 (50) 16 (50) 20 (63) 12 (37) 18 (56) 14 (44) 9 (28) 23 (72)
Distal 65 33 (51) 32 (49) 40 (62) 25 (28) 44 (68) 21 (32) 29 (45) 36 (55)






T1a 6 4 (67) 2 (33) 5 (83) 1 (17) 4 (67) 2 (33) 4 (67) 2 (33)
T1b 30 14 (47) 16 (53) 21 (70) 9 (30) 20 (67) 10 (33) 15 (50) 15 (50)
T2 17 5 (29) 12 (71) 12 (71) 5 (29) 9 (53) 8 (47) 6 (35) 11 (65)
T3 32 16 (50) 16 (50) 19 (59) 13 (41) 19 (59) 13 (41) 11 (34) 21 (66)
T4a 11 6 (55) 5 (45) 3 (27) 8 (73) 7 (64) 4 (39) 2 (18) 9 (82)
T4b 4 4 (100) 0 (0) 1 (25) 3 (75) 4 (100) 0 (0) 1 (25) 3 (75)






N0 55 26 (47) 29 (53) 37 (67) 18 (33) 35 (64) 20 (36) 26 (47) 29 (53)
N1 15 6 (40) 9 (60) 11 (73) 4 (27) 10 (67) 5 (33) 7 (47) 8 (53)
N2 12 7 (58) 5 (42) 4 (33) 8 (67) 8 (67) 4 (33) 3 (25) 9 (75)
N3/a/b 16 10 (63) 6 (37) 8 (50) 8 (50) 10 (63) 6 (37) 3 (19) 13 (81)






IA 30 15 (50) 15 (50) 22 (73) 8 (27) 19 (63) 11 (37) 16 (53) 14 (47)
IB 13 5 (39) 8 (62) 9 (69) 4 (31) 10 (77) 3 (23) 7 (54) 6 (42)
IIA 18 8 (44) 10 (56) 11 (61) 7 (39) 9 (50) 9 (50) 5 (28) 13 (72)
IIB 7 3 (43) 4 (57) 5 (71) 2 (29) 5 (71) 2 (29) 4 (57) 3 (43)
IIIA 10 6 (60) 4 (40) 3 (30) 7 (70) 5 (50) 5 (50) 1 (10) 9 (90)
IIIB 8 3 (38) 5 (62) 7 (88) 1 (12) 5 (63) 3 (37) 4 (50) 4 (50)
IIIC 4 3 (75) 1 (25) 0 (0) 4 (4) 3 (75) 1 (25) 0 (0) 4 (100)







n Total 93 43 50 56 37 58 35 35 58
n E v e n t s 5 6 2 63 0 3 2 2 43 1 2 5 1 6 4 0
Median 34.066.2 48.0613.5 44.869.2 33.669.3 39.369.5 34.0610.2 54.566.3 28.068.6
95% CI 22.0–46.1 21.5–74.5 26.9–62.8 15.3–52.0 20.7–57.8 14.1–53.9 42.2–66.9 11.0–44.9
Correlation of the spatial distribution of LGR5




£log-rank test (Mantel-Cox) with a 95% confidence interval (CI). Number (n) and percentage (%) of LGR5
+ cases. SD=standard deviation.
doi:10.1371/journal.pone.0035486.t002
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(Roche). The plasmid was verified by digestion with NheI and
BamHI and DNA sequencing using ABI PRISM BigDye
Terminator Cycle Sequencing Ready Reaction Kits, Version 2.0
(PE Applied Biosystems, Langen, Germany).
Cell culture and transfection
The human gastric cancer cell line MKN74 was obtained from
the Japanese Health Science Research Resource Bank (Osaka,
Japan), and MKN45 from the German Collection of Microor-
ganisms and Cell Cultures (Braunschweig, Germany). HEK293
EBNA cells were purchased by Invitrogen (Carlsbad, CA,
USA). The cells were grown in RPMI 1640 Medium (MKN74,
MKN45) or Dulbecco’s Modified Eagle Medium (HEK293)
supplemented with 10% (MKN74, HEK293) or 20% (MKN45)
fetal bovine serum, 100 U/mL penicillin and 100 mg/mL
streptomycin (PAA Laboratories GmbH, Pasching, Austria).
DNA transfection of HEK293 EBNA, MKN74 and MKN45
cells was done using Lipofectamine LTX reagent (Invitrogen)
according to the manufacturer’s instruction. Briefly, cells were
cultured in six-well plates. Stable transfection of MKN74 and
MKN45 with expression plasmids was performed as pre-
viously described [7]. For transient transfection of HEK293 cells
1 mg plasmid DNA and 5 ml Lipofectamine LTX reagent were
diluted in 500 ml Dulbecco’s Modified Eagle Medium without
serum, respectively. After incubation for 30 minutes at room
temperature, the mixture was added to HEK293 cells. Forty-eight
hours after transfection, transfected cells were harvested and RNA
or proteins were isolated. Cells transfected with the vector
pcDNA3.1(2) alone and untransfected cells served as negative
controls.
Immunofluorescence
Twenty-four hours after seeding on CultureSlides (BD Biosci-
ences, Erembodegem, Belgium), cells were washed with phos-
phate-buffered saline, fixed in 7:3 acetone:methanol (20 minutes,
220uC) and subsequently permeabilized with 0.1% Triton-X
(5 minutes, room temperature). Slides were then incubated with c-
Myc mouse monoclonal antibody (Clontech, Mountain View, CA,
USA) over night at 5uC in a moist chamber, followed by an anti-
mouse Alexa Fluor 555 conjugated secondary antibody (Invitro-
gen). To detect the successful transfection of LGR5, cells were
incubated with anti-LGR5-antibody followed by an anti-rabbit
secondary antibody conjugated with Alexa Fluor 488 (Invitrogen)
each for one hour at room temperature. Omission of primary
antibodies on LGR5 transfected HEK293 EBNA cells served as
negative control. Mounting and counterstaining was done with
VECTASHIELD Hard-Set including DAPI (Vector Laboratories,
Inc., Burlingame, CA, USA).
Immunocytochemistry
Immunocytochemical staining was performed on formalin-
fixed, paraffin-embedded MKN45 gastric cancer cells. For this
purpose, MKN45 cells were embedded in small agarose beads as
described previously [8]. Further processing and immunostaining
with anti-LGR5-antibody (dilution 1:1000) was carried out
according to the immunohistochemical analyses of human tissue
sections (see below). Omission of the primary antibody on LGR5
transfected MKN45 cells served as negative control, while the
specificity of anti-LGR5-antibody staining was confirmed by
incubating the antibody with the immunizing blocking peptide.
Western blotting
Protein lysates were obtained by incubating human gastric tissue
and cultured gastric cells with ProteoJET
TM Mammalian Cell
Lysis Reagent (Fermentas, St. Leon-Rot, Germany) and protease
inhibitor cocktail (Complete EDTA-free, Roche). Protein samples
were denaturated in Laemmli buffer (60 mM Tris-HCl pH 6.8,
2% sodium dodecyl sulphate, 10% glycerol, 5% b-mercaptoeth-
anol and 0.01% bromphenol blue) by heating at 95uC for ten
minutes and were subsequently loaded on 4% to 16.5% SDS
polyacrylamide gels and visualized by staining with Coomassie
blue. After separation, proteins on unstained polyacrylamide gels




negative LGR5 positivep value
Patients, n (%) 487 243 (50) 244 (50)
Age (mean ± SD) 68610.8 68611.4
Age, years, n (%) 0.635*
,65 289 144 (50) 145 (50)
$65 180 85 (47) 95 (53)
Gender, n (%) 0.575*
Male 304 155 (51) 149 (49)
Female 183 88 (48) 95 (52)
Tumour type, n (%) 0.422*
Intestinal 189 88 (47) 101 (53)
Diffuse 218 114 (52) 104 (48)
Mixed 42 23 (55) 19 (45)
Localization, n (%) 1.000*
Proximal 149 74 (50) 75 (50)
Distal 315 156 (50) 159 (50)
T category, n (%) 0.704*
pT1a 14 7 (50) 7 (50)
pT1b 46 21 (46) 25 (54)
pT2 56 23 (41) 33 (59)
pT3 193 102 (53) 91 (47)
pT4a 133 66 (50) 67 (50)
pT4b 43 23 (53) 20 (47)
Lymph nodes, n (%) 0.414*
No metastases 134 62 (46) 72 (54)
Metastases 335 170 (51) 165 (49)
N category, n (%) 0.884*
pN0 138 65 (47) 73 (53)
pN1 71 38 (54) 33 (46)
pN2 82 40 (49) 42 (51)
pN3 69 38 (55) 31 (45)
pN3a 71 34 (48) 37 (52)
pN3b 50 25 (50) 25 (50)
Grade, n (%) 0.088*
G1 10 6 (60) 4 (40)
G2 103 41 (40) 62 (60)
G3/G4 357 183 (51) 174 (49)
Correlation of LGR5 expression with clinico-pathological patient characteristics.
*Fisher’s exact test. Number (n) and percentage (%) of LGR5-positive cases.
SD=standard deviation.
doi:10.1371/journal.pone.0035486.t003
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Freiburg, Germany), immunoblotted with the anti-LGR5-anti-
body (dilution 1:20,000) and an anti-b-actin-antibody (1:10,000;
clone AC-15, Sigma-Aldrich, St. Louis, MO, USA) to ensure
equal loading amounts. Membrane bound HRP labelled second-
ary antibodies (DakoCytomation, Glostrup, Denmark) were
detected by enhanced chemiluminescence using the ECL system
(Amersham). Omission of the primary antibody served as negative
control, while the specificity of anti-LGR5-antibody staining was
confirmed by incubating the antibody with the immunizing
blocking peptide.
Histology
For histological analyses, tissue samples were fixed in 10%
neutralized formalin and embedded in paraffin. Deparaffinized
sections were stained using hematoxylin and eosin (H&E). Gastric
carcinoma was classified according to the WHO classification [9].
The pTNM stage was determined according to the 7
th edition of
the International Union Against Cancer [10].
Tissue micro array construction
Formalin-fixed and paraffin-embedded tissue samples were
used to generate tissue micro arrays as described previously [11].
Four micrometer sections of the resulting tumour tissue micro
array block were cut for further analysis. Successful transfer of
tumour tissue was confirmed microscopically using H&E-stained
sections.
Immunohistochemistry
For immunohistochemistry, formalin-fixed and paraffin-embed-
ded sections were used. Immunostaining was carried out with the
anti-LGR5-antibody (dilution 1:1000), a monoclonal antibody
directed against CD44 (1:200; Novocastra Laboratories Ltd,
Newcastle, GB) and commercial polyclonal antibodies directed
against LGR5 (LGR5
com, 1:400; Abcam, Inc., Cambridge, MA,
USA), ADAM17 (dilution 1:50; Sigma-Aldrich) and Musashi-1
(1:500; Chemicon International Inc., Temecula, CA, USA).
Following 20 minutes blocking with hydrogen peroxide block
(Thermo Scientific, Waltham, MA, USA), 5 minutes treatment
with Ultra V Block (Thermo Scientific) and incubation with the
primary antibody was done in a moist chamber at room
temperature for 30 minutes. Slides were washed between steps
with Tris-buffered saline (TBS). Immunoreactions were visua-
lized with the n-Histofine Simple Stain MAX PO System
(Nichirei Bioscience, Tokyo, Japan) and DAB substrate (Linaris,
Wertheim-Bettingen, Germany). For double staining of LGR5
with CD44, ADAM17 and Musashi-1, free binding sites were
blocked with mouse-IgG and rabbit-IgG control (Abcam) diluted
in antibody diluent (ZYTOMED Systems, Berlin, Germany)
after DAB-treatment. The specimens were counterstained with
hematoxylin. Omission of the primary antibody served as
negative controls. Non-neoplastic human stomach (CD44) and
brain tissue (LGR5
com, LGR5 and Musashi-1) served as positive
controls.
Evaluation of immunostaining
Immunostaining of non-neoplastic epithelium and tumour cells
was scored by applying an immunoreactivity scoring system (IRS).
Briefly, category A documented the intensity of immunostaining as
0 (no immunostaining), 1 (weak), 2 (moderate), and 3 (strong).
Category B documented the percentage of immunoreactive cells as
0 (negative), 1 (scattered positive cells; #1%), 2 (2–10% positive
cells), 3 (11–50%), 4 (51–80%) and 5 (.80%). The addition of
category A and B resulted in an IRS ranging from 0 to 8 for each
individual case. The distributional changes of LGR5
+ cells in 100
whole mount sections of intestinal type gastric cancer was scored
as follows: the number of immunoreactive cells was categorized as
0 (negative), 1 (,10 positive cells), 2 (10–50 positive cells) and 3
(.50 positive cells) separately for the luminal surface, tumour
centre and the invasion front.
Statistical analyses
Statistical analyses were done using the PASW Statistics 18
statistical package (SPSS Inc., Chicago, IL, USA). Comparisons
among groups were tested by use of Fisher’s exact test. Correlation
of LGR5 expression within one group was established by Kendall’s
tau rank-order correlation. Survival curves were fitted with the
Kaplan-Meier method and differences in survival assessed by the
log rank test. The significance of correlations of LGR5 expression
in primary tumours and corresponding non-malignant tissue was
assessed by the Wilcoxon test. Real-time RT-PCR data, which
were evaluated with a paired two-sided t-test, got logarithmized to
obtain approximately normally distributed data. P-values,0.05
were considered as statistically significant.
Results
LGR5-mRNA is differentially expressed in hepato-
gastrointestinal carcinomas
LGR5 was reportedly expressed in murine stem cells of the
intestinal crypts [12] and was frequently overexpressed in colon
cancer cell lines [13]. To investigate its expression in non-
neoplastic and neoplastic human tissue, we evaluated the
transcriptional expression of LGR5 in human clinical specimens
composed of a broad range of hepato-gastrointestinal carcinomas.
Real-time RT-PCR analysis was carried out on a series of 105
patients comprising malignant and corresponding non-malignant
tissue, obtained from the same patients, of eight different tumour
types: oesophagus [Barrett’s adenocarcinomas (9 patients) and
squamous cell carcinomas (7)], stomach [intestinal (19) and diffuse
type (21) gastric carcinomas], liver [HCCs (4), CCs (6)], colon (19)
and rectum (20; Table 1).
LGR5-mRNA was significantly differentially expressed in
adenocarcinomas of the oesophagus (p=0.007), stomach [intesti-
nal type (p=0.006) and diffuse type (p=0.013)], liver [CCs
(p=0.022)], colon (p,0.001) as well as rectum (p=0.002)
compared with the matched non-neoplastic tissue. However, no
differential expression was found in squamous cell carcinomas of
the oesophagus (p=0.503) and HCCs compared with the
corresponding non-neoplastic tissues (p=0.545; Figure 1).
A polyclonal anti-LGR5-antibody detects human LGR5
transfected into HEK293 and MKN45 cells
To further explore the histoanatomical distribution of LGR5 in
human tissues and to investigate its clinico-pathological signifi-
cance, an LGR5-specific antibody was raised, since the commer-
cially available antibodies did not meet our demands (Figure 2A).
To exclude cross reactivity of the newly generated antibody with
the most structurally similar LGRs, LGR4 and LGR6, we
performed a sequence alignment with the National Center for
Biotechnology Information alignment tool in advance (data not shown).
No sequence homology was found with LGR4 or LGR6 in the
region of the LGR5 peptide we used for immunization. For the
selection of a highly specific antibody against LGR5, cloned
full length cDNA was transfected into HEK293 EBNA cells and
used as a positive target performing immunofluorescence. The
LGR5 cDNA was directly tagged with a myc-epitope, which
LGR5 Expression in Hepato-Gastrointestinal Cancer
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antibody. Using immunofluorescence, binding of the anti-myc tag
antibody was found after incubation with LGR5/HEK293 cells,
but not in empty vector-transfected cells (vector/HEK293),
untransfected HEK293 cells, or in the negative control of
LGR5/HEK293 cells incubated with antibody diluent instead of
the primary antibody. The same result was obtained when we used
the anti-LGR5-antibody (Figure 3), demonstrating specific label-
ling of LGR5.
The specificity of LGR5-immunolabelling was further validated
using formalin-fixed and paraffin-embedded MKN45 gastric
cancer cells. The cells were prepared and stained in a manner
that parallels the processing of clinical human tissue specimens.
Immunocytochemical analyses on paraffin sections revealed a
positive staining of anti-LGR5-antibody on MKN45 cells stably
transfected with LGR5 cDNA (LGR5/MKN45). Instead, empty
vector-transfected MKN45 cells (vector/MKN45), as well as the
negative control (omission of the primary antibody) and the
peptide control (pre-incubation of the antibody with its immuniz-
ing blocking peptide) of LGR5/MKN45 cells showed no binding
of the antibody (Figure S1).
LGR5 protein is specifically detected by anti-LGR5-
antibody in human transfected MKN74 cells
The human gastric cancer cell lines MKN74, known to posses a
moderate LGR5-mRNA expression (data not shown) and human
non-neoplastic stomach, exhibiting very low LGR5 expression
(Figure 1) were chosen to characterize the reactivity and specificity
of the anti-LGR5-antibody on protein level.
In western blot analysis, LGR5 protein was recognized
specifically by the monospecific anti-LGR5-antibody at a dilution
of 1:20,000. It identified one band with an apparent molecular
weight of 100 kDa in MKN74 cell lysates (Figure 4), which
matches the molecular mass calculated for LGR5 protein. In
contrast, no band was detected in lysates of human non-neoplastic
stomach tissue, which excludes a cross reactivity of anti-LGR5-
antibody with cellular proteins. In line with mRNA expression
Figure 1. LGR5 expression in hepato-gastrointestinal tissues measured by Real-time RT-PCR. Boxplots depicting overall distribution of
LGR5 comparing malignant versus adjacent non-malignant tissue in (A) Barrett’s adenocarcinoma and (B) squamous cell carcinoma of the
oesophagus, (C) intestinal type gastric cancer, (D) diffuse type gastric cancer, (E) hepatocellular carcinoma, (F) cholangiocarcinoma, (G) colon and (H)
rectal carcinoma.
doi:10.1371/journal.pone.0035486.g001
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MKN74 cells stably transfected with LGR5 cDNA, compared to
MKN74 control cells transfected with the empty vector. LGR5
protein expression in human non-neoplastic stomach mucosa was
beyond the detection limit of western blotting, displaying no band.
Omission of the anti-LGR5-antibody or previous incubation of the
antibody with its immunizing blocking peptide displays no protein
bands, respectively. Detection of b-actin protein (about 43 kDa;
Figure 4) served as a loading control and confirmed evenly loaded
protein amounts in all lanes.
Figure 2. Putative stem cell marker expression in gastric specimens. Representative images of immunohistochemical staining for LGR5
com
(A) and LGR5 (B) in a gastric cancer specimen. Following separate staining for ADAM17 (C) and LGR5 (D), as well as double staining for ADAM17 (red
colour) and LGR5 (brown colour; E) in a serial section of healthy gastric mucosa. Comparing healthy stomach mucosa (F, G) and neoplastic gastric
tissue (H), Msh-1
+/LGR5
2 (red colour), Msh-1
2/LGR5
+ (brown colour; F) as well as Msh-1
+/LGR5
+ cells (G) are present. Predominantly CD44
+/LGR5
+
cells in double staining experiments for CD44 (red colour) and LGR5 (brown colour) in healthy (I) and neoplastic (J) gastric mucosa. Double positive
cells are indicated by arrows, arrowheads mark scattered single stained cells. Original magnifications 6400 (A–J); 6600 (E).
doi:10.1371/journal.pone.0035486.g002
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of the hepato-gastrointestinal tract
The expression and histoanatomical distribution of LGR5 was
subsequently studied by immunohistochemistry in a series of 127
tissue slides obtained from corresponding non-neoplastic and
neoplastic tissue of the hepato-gastrointestinal tract, comprising
the oesophagus (14 patients), stomach (32), liver (24), pancreas
(17), colon (20), and rectum (20; Table 1). Out of this cohort
neoplastic and corresponding non-neoplastic tissue samples of
105 patients were also studied on the transcriptional level (see
above).
LGR5 expression of the overall cohort was positive in 65 cases
(51%) of all non-malignant tissues and 103 cases (81%) of all
cancer tissues. Localization of LGR5 expression was observed as
mainly cytoplasmatic, whereas also a sporadic membrane or core
membrane accentuated expression occurred. An LGR5-immuno-
reactivity was found in all tissue components, i.e. stroma cells,
endothelial cells, cells in the non-neoplastic epithelium and in
cancer cells (Figure 5). LGR5-immunoreactivity in stroma cells
was observed in 49 (39%) of all non-malignant tissues and in 80
cases (63%) of all cancer tissues. An endothelial immunoreactivity
of LGR5 was observed in 42 cases (33%) of all tissues.
In the non-malignant epithelium, LGR5 was usually found in
few scattered cells close to the basement membrane of the gastric
mucosal unit, pancreatic ducts, and the colorectal crypts. LGR5
was not found in the squamous epithelium of the oesophagus,
intrahepatic bile ducts, and hepatocytes (Figure 6). For all tissue
types apart from oesophageal tissue the mean value of IRS was
significantly higher for tumour tissue relative to the matched non-
malignant tissue, confirming our findings on the transcriptional
level (Table 1).
LGR5 is present in scattered cells of the normal gastric
mucosa
The existence of multipotent stem cells within the murine
stomach was demonstrated by clonal marking studies. The
definitive identification of these cells failed so far owing the
unavailability of specific endogenous markers [14]. Using serial
sections obtained from a sleeve resection specimen, which is
usually obtained for the treatment of overweight, and showed no
histological evidence of gastric cancer or chronic gastritis, we
searched for LGR5
+ epithelial cells. Interestingly, scattered
LGR5
+ cells were found in the mucous neck region between the
foveolae and glands (Figure 7).
LGR5 is coexpressed with other potential gastric stem
cell or progenitor cell markers
Stem cells of non-neoplastic tissue and CSCs are usually
identified and validated by the expression of more than a single
stem cell marker [15]. Using immunohistochemistry, we next
analyzed the coexpression of LGR5 with other putative CSC
markers, i.e. ADAM17, CD44, Musashi-1 [16–21]. ADAM17 was
selected, since previous studies identified ADAM17 as a putative
stem cell marker of the stomach [8]. Immunostaining (either
double staining or staining of serial sections) was carried out on a
gastric cancer specimen and on healthy uninflammed gastric
Figure 3. Immunofluorescence staining with anti-LGR5-antibody. Immunofluorescence staining of HEK293 EBNA cells with LGR5 specific
antibody (green) and anti-myc tag antibody (red). Cells were counterstained with DAPI to show the cell nucleus (blue). Cells transfected with the myc-
tagged LGR5 cDNA (first panel) compared to control cells, transfected with the empty vector (control empty vector); leaving untransfected (control
untransfected); or incubated without the primary antibodies , respectively. Original magnifications 6400.
doi:10.1371/journal.pone.0035486.g003
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scattered cells showed positive immunostaining for one and/or the
other putative stem cell marker. Interestingly, the non-neoplastic
gastric mucosa harbours cells which are each ADAM17
+/LGR5
+
(representing approximately one third of all immunoreactive cells)
and ADAM17
+/LGR5
2 (two thirds), and ADAM17
2/LGR5
+
(few scattered cells; Figure 2C–E).
Musashi-1 (Msh-1) was described as a putative stem cell marker
in the mouse intestine and human stomach [18,22] and as a CSC
marker in tumours [23]. In neoplastic and non-neoplastic gastric
tissue positive stained cells composed predominantly of Msh-1
+/
LGR5
2 (approximately two thirds of all immunoreactive cells), to
a lesser extent of Msh-1
+/LGR5
+ (one third), and few Msh-1
2/
LGR5
+ cells (Figure 2F–H). Finally the surface marker of
colorectal and gastric cancer stem cells CD44 [21,24] revealed a
distribution comparable with Msh-1 (Figure 2I, J). Collectively,
these findings support the hypothesis that our anti-LGR5-antibody
detects cells with stem cell expression patterns in the human gastric
mucosa.
The spatial distribution of LGR5
+ cells changes during
tumourigenesis
The sequential changes in the gastric mucosa that precede the
development of invasive cancer are known as the ‘precancerous
cascade’, first described in 1975, where normal gastric mucosa is
transformed by chronic atrophic gastritis and develops multifocal
atrophy and intestinal metaplasia, followed by the appearance of
dysplasia and finally invasive carcinoma [25]. Next we tested the
hypothesis that the aforementioned histopathological changes of
the stomach mucosa are associated with a reallocation of the
LGR5
+ putative stem cells. We systematically explored the
histoanatomical distribution of LGR5
+ cells in 100 patients with
intestinal type gastric cancer. Whole mount tissue sections were
used which enclosed non-neoplastic, metaplastic and neoplastic
cancer tissue. It was readily apparent that the histoanatomical
distribution of LGR5
+ cells changed (see Figure 7): in non-
neoplastic and non-metaplastic stomach mucosa, few scattered
LGR5
+ cells were found in the mucous neck region (Figure 7A, E).
In the intestinal metaplasia, a slightly increased number of LGR5
+
cells were localized at the bottom of the metaplastic crypts
(Figure 7B, F). However, in intestinal type gastric cancer the
localization and number of LGR5
+ cells was strikingly changed. In
gastric cancer, LGR5
+ cells were present at the luminal surface
(Figure 7C, G), in the tumour centre (between luminal surface and
invasion front) and at the invasion front (Figure 7D). Most
interestingly, the distribution of LGR5
+ gastric cancer cells showed
distinctive patterns: the LGR5
+ cells occurred in cohesive patches
of a variable number of tumour cells ranging from ,10, 10–50
and even .50 tumour cells, often forming gradients of decreasing
staining intensities. The overall distribution of these LGR5
+
tumour cell patches was uneven and inhomogeneous. Collectively,
we observed an increase in the number and intensity of LGR5
+
cells from non-neoplastic epithelia to gastric cancer supporting our
Real-time RT-PCR and immunohistochemistry data of matched
(non-neoplastic versus neoplastic) patient cases (see Table 1). Our
findings of the altered distribution pattern of LGR5
+ cells is
consistent with those described by Takeda et al. for colorectal
cancer [26].
Figure 4. Validation of the anti-LGR5-antibody by western blotting. Coomassie blue staining (Coomassie) depicts the quality of loaded total
protein lysates. In western blot analysis the anti-LGR5-antibody (1:20,000) detects a single band in protein lysates of stably transfected MKN74 cells,
overexpressing LGR5 (MKN74+LGR5), a weaker band of cells transfected with the control empty vector (MKN74 + empty vector), and no band in
lysates of human non-neoplastic stomach mucosa, respectively. On a parallel blot no target bands are visible when the anti-LGR5-antibody was pre-
incubated with its immunizing blocking peptide (peptide blocking). The top bands (100 kDa, arrow) display the LGR5 protein, whereas the bottom
bands (,43 kDa, arrow) depict b-actin, used as a loading control.
doi:10.1371/journal.pone.0035486.g004
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correlates with local tumour growth and nodal spread
It is postulated that CSC influence patient prognosis by their
ability to form tumour cell colonies, an indispensable pre-requisite
for metastatic spread and disease recurrence. To further explore
the significance of LGR5 for gastric cancer, we correlated the
expression of LGR5 in intestinal type gastric cancer with various
clinico-pathological patient characteristics. Since the spatial
distribution of LGR5
+ cancer cells and hence the putative stem
cell niche may be important for its tumour biological significance,
we investigated each compartment, i.e. luminal surface, tumour
centre and invasion front, separately. This showed a significant
correlation between the presence of LGR5
+ cancer cells in the
tumour centre and the local tumour growth (T-category; Table 2).
A detailed analysis of the patient survival further revealed that
patients with LGR5
+ cancer cells at the luminal surface lived
longer (compared with LGR5-negative cases at the luminal
surface), while those with LGR5
+ tumour cells in the tumour
centre and at the invasion front lived shorter compared with
LGR5-negative cases at these sites (Table 2; Figure 8). This
indicated that the biological significance of LGR5
+ cancer cells
may depend on their spatial distribution within the tumour mass.
In the next step we grouped all patients together with LGR5
+
tumour cells in the tumour centre and/or at the invasion front.
This now showed that LGR5 expression correlated significantly
with the local tumour growth (T-category), nodal spread (N-
category) and tumour stage. Furthermore, patients with LGR5
+
tumour cells had a shorter median survival (28.068.6 months)
Figure 5. Immunohistochemical staining of LGR5 in colon tissues. LGR5 expression in normal colonic mucosa (A), membranous (B) and
cytoplasmic (C) staining in corresponding colon cancer cells. Arrows mark scattered immunoreactive cells within the crypt base. Asterisk (*) marks the
luminal site. Variable LGR5-immunoreactivity of endothelial cells was found in cancer tissue: The presence of LGR5-immunonegative endothelial cells
(D) was confirmed by CD34 (E) using serial sections. Note strong endothelial LGR5-immunoreactivity in another case of colon cancer (F). (G)
Expression of LGR5 in desmoplastic stroma cells. Original magnifications 6200 (A); 6400 (B–G).
doi:10.1371/journal.pone.0035486.g005
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Figure 8). Although, this difference did not reach statistical
significance, it was interesting to note that the confidence intervals
of LGR5-positive and -negative cases barely overlapped (Table 2;
Figure 8).
Tissue micro arrays are not applicable to study the
tumour biological significance of LGR5
Tissue micro arrays (TMA) are commonly used to study the
tumour biological significance of novel biomarkers [27]. However,
as shown above, the distribution of LGR5
+ cells is not random and
Figure 6. LGR5-immunoreactivity in hepato-gastrointestinal tissues. Expression of LGR5 in normal oesophageal mucosa (A) compared with
an adenocarcinoma (B) and a squamous cell carcinoma (C). LGR5 expression in the normal liver (D) compared with hepatocellular carcinoma (E),
normal (F) and malignant (G) epithelium of the bile duct, as well as non-neoplastic (H) and neoplastic (I) pancreatic tissue. Original magnifications
6400.
doi:10.1371/journal.pone.0035486.g006
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Finally we wished to test, whether TMAs are suitable to study the
tumour biological significance of putative CSC markers. We
constructed TMAs from a series of 487 patients, who underwent
partial or complete gastrectomy for adenocarcinomas of the
oesophago-gastric junction or stomach. Survival data were
available from 466 patients. 333 patients died during follow-up
and 51 were still alive at the endpoint of our analysis. The median
follow-up for those patients still alive was 60.9 months (range 14.3–
129.9 months).
LGR5
+ tumour cells were found in 244 of 487 (50%) patients. A
strong cytoplasmic and membranous immunoreaction was ob-
served in 36 (7.4%) cases and a weak to moderate staining in 208
(42.7%) cases. 243 tumours (50%) lacked LGR5-immunoreactivity
(Table 3). Next we studied the correlation between the expression
of LGR5 and various clinico-pathological patient characteristics.
The expression of LGR5 by tumour cells did not correlate with
any clinico-pathological patient characteristic, including patient
survival (Table 3). However, patient survival correlated signifi-
cantly with tumour type (p=0.007), T-category (p,0.001), the
presence of lymph node metastases (p,0.001), N-category
(p,0.001) and tumour grade (p,0.001; Table 4).
Discussion
Carcinomas of the hepato-gastrointestinal tract still head the
statistics of cancer deaths worldwide [28]. There is a need for new
molecular-targeted therapeutic approaches in order to improve
the poor prognosis of hepato-gastrointestinal cancers. Targeting
cancer stem cells (CSCs) might be a novel approach to improve
patient outcome. CSCs like normal tissue stem cells (SCs) are
capable of self-renewal, asymmetric division and multilineage
differentiation enabling them to efficiently seed new tumours upon
inoculation into recipient hosts, such as mice [29,30]. They are
likely to depend on a stem cell niche and the expression of stem
cell markers is influenced and modulated by the local cellular and
acellular environment [31]. The identification of stem cell
markers, and the characterization and validation of CSC for solid
human tumours remains a major obstacle. The validity of the CSC
hypothesis for solid human tumours can only be confirmed
circumstantially.
Recently, Barker and colleagues used lineage labelling to show
that LGR5 expressing cells represent actively dividing multi-
potent stem cells of the gastric and intestinal mucosa of mice [6].
Based on this observations we hypothesized that LGR5, may
have an impact on tumourigenesis in the human gastrointestinal
tract.
Using a monospecific anti-LGR5-antibody, we were able to
identify LGR5 expressing cells in non-neoplastic and neoplastic
tissue. Few, scattered LGR5
+ cells were found in close proximity to
the basement membrane of non-neoplastic pancreatic ducts, the
colorectal crypts, and the stomach. All these sites are compatible
with the histoanatomical locations of stem cells in humans
[6,26,32]. LGR5 expressing cells at the base of antral glands
Figure 7. Staining patterns of LGR5 in gastric cancer tissues. Distribution patterns of LGR5
+ cells in healthy gastric mucosa (A, E), an intestinal
metaplasia (B, F), and a gastric adenocarcinoma (C, G) with its invasive front (D). The upper panel shows representative immunohistochemical
staining with an anti-LGR5-antibody on whole mount sections of intestinal type gastric cancers. The lower panel depicts the corresponding schematic
model of the distributional changes in different stages of gastric tumourigenesis. Arrows mark LGR5
+ cells. Asterisk (*) marks the luminal site. The
black line highlights the tumour host interface (invasion front). Original magnifications 6200.
doi:10.1371/journal.pone.0035486.g007
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to all antral unit cells in the mouse [6]. Similarly, we show that
LGR5 is expressed by cells at the base of the human gastric
glandular unit, which may represent those stem cells described by
Barker and colleagues in the murine stomach.
Inspired by the work of Baker et al. other researchers continued
to characterize the Wnt target gene and G-protein coupled
receptor in mice [12,33,34], human cell cultures [16,35] and
cancer specimens [13,24,36]. After all LGR5 is currently
considered to be the most selective and promising marker of
Figure 8. Survival of the validation cohort. Kaplan-Meier curves depicting overall survival of the validation cohort according to the distribution
of LGR5
+ gastric cancer cells at the luminal surface (A), the tumour centre (B), and the invasion front (C). (D) Survival of grouped patients with LGR5
+
tumour cells in the tumour centre and/or at the invasion front. P-values were calculated with the log rank test.
doi:10.1371/journal.pone.0035486.g008
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systematic analysis of LGR5 expression in a broad range of human
hepato-gastrointestinal tumours and their corresponding normal
tissue was as yet missing. With our experimental approach, we
provide evidence that LGR5 is significantly up-regulated in a large
variety of human hepato-gastrointestinal cancers relative to the
tumour adjacent normal tissue. In support of this contention, the
expression of LGR5 in intestinal type gastric cancer correlated
with the local tumour growth, nodal spread (as an indicator for the
ability of colony formation) and patient survival. Nonetheless,
whether LGR5 up-regulation itself contributes to cancer progres-
sion or simply is a surrogate marker, necessitates further
investigations.
As a matter of course, LGR5 is not the only marker of stemness
in the stomach. Several markers including ADAM17 [8], CD44
[19], and Musashi-1 [37] were reported as putative markers of SC
Table 4. Patient survival related to several clinico-pathological patient characteristics in tissue micro arrays.
Patients Events Median survival, months (95% Cl) Log rank test
Overall survival 466 333 15.5 (13.1–17.9)
Age, years 0.186
,65 288 210 13.661.5 (10.7–16.5)
$65 178 123 16.662.2 (12.4–20.8)
Tumour type 0.007
Intestinal 181 124 19.563.1 (13.4–25.6)
Diffuse 209 154 13.261.3 (10.8–15.7)
Mixed 41 32 10.661.9 (7.0–14.3)
Localization 0.062
Proximal 147 113 12.661.0 (10.7–14.6)
Distal 298 205 17.962.0 (13.9–22.0)
T category ,0.001
pT1a 14 2 123.5649.7 (26.1–220.9)
pT1b 44 16 64.9
pT2 50 28 35.2610.3 (14.9–55.4)
pT3 186 137 16.762.0 (12.8–20.6)
pT4a 128 109 9.861.9 (6.1–13.4)
pT4b 43 40 9.361.6 (6.1–12.5)
Lymph node metastases ,0.001
No metastases 128 52 55.0615.8 (24.0–86.0)
Metastases 322 270 11.961.0 (9.9–13.9)
N category ,0.001
pN0 132 53 55.5618.7 (18.9–92.0)
pN1 67 46 20.063.7 (12.9–27.2)
pN2 78 63 16.662.0 (12.8–20.5)
pN3 68 60 8.361.2 (5.9–10.8)
pN3a 69 61 9.461.9 (5.5–13.2)
pN3b 48 46 6.461.7 (3.0–9.8)
Grade ,0.001
G1 10 4 56.0621.0 (14.8–97.0)
G2 104 60 34.068.1 (18.1–49.8)
G3/G4 340 260 12.760.8 (11.1–14.3)
LGR5 at tumour centre and/or
invasion front
0.100
LGR5-positive tumour cells 58 40 28.068.6 (11.0–44.9)
LGR5-negative tumour cells 35 16 54.566.3 (42.2–66.9)
LGR5 expression assessed by tissue
micro array technology
0.915
LGR5-positive tumour cells 237 172 15.561.5 (12.6–18.3)
LGR5-negative tumour cells 228 160 14.761.5 (11.7–17.7)
Patient survival according to several clinico-pathological parameters and the expression of LGR5 in tumour cells assessed in tissue micro arrays and whole mount tissue
sections, respectively. P-values were calculated with the log rank test (Mantel-Cox) with a 95% confidence interval (CI).
doi:10.1371/journal.pone.0035486.t004
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LGR5-antibody was initially confirmed by western blotting and
immunofluorescence staining. The apparent coexpression and
colocalization of above-mentioned putative stem cell markers and
LGR5 in double staining experiments assures our conjecture that
the LGR5-antibody identifies those repeatedly described LGR5
+
SCs and CSCs in human tissues. After all the expression of LGR5
and other putative stem cell markers appear to be early events and
to remain high in neoplastic gastric tissue.
The assumption that LGR5 is a stem cell marker of both non-
neoplastic and neoplastic gastric epithelia raises several interesting
questions. LGR5 is a member of the canonical Wnt-signalling
cascade, which forms a signalling gradient in the intestinal crypt
and thereby regulates cell proliferation and differentiation [38].
LGR5 highlights the stem cell niche and loss of LGR5 expression
indicates the growth direction of the descending cells [14]. As
demonstrated by our immunohistochemical studies, the number
and histoanatomical distribution of LGR5
+ cells is variable. In the
non-neoplastic mucosa, the stem cells differentiate into two
directions, i.e. towards the luminal surface forming the foveolar
epithelium, and into the abluminal compartment forming gastric
glands [14]. This bidirectional differentiation seems to be lost in
intestinal metaplasia, where LGR5
+ cells were present at the
metaplastic crypt base. The direction of cell differentiation must
have changed, now pointing only towards the luminal surface.
While a gradient of LGR5 expression was hardly detectable in
non-neoplastic mucosa, gastric cancer frequently showed a
gradient of LGR5 expression. Most surprisingly, a very strong
expression of LGR5 was found at the luminal surface of gastric
cancer with decreasing staining intensities of the adjacent
abluminal cells. This observation leads to the contention that the
putative stem cell niche has become far more mobile by obtaining
migratory capabilities and less restricted with regard to the spatial
orientation of its derivatives, which could now also proliferate
towards the abluminal site of the mucosa, supporting an invasive
growth direction. Furthermore, the overall expression pattern of
LGR5 in gastric cancer is compatible with the loss of control of the
growth direction of neoplastic epithelia. The uneven distribution
of CSC and the seemingly ‘‘uncontrolled’’ or ‘‘chaotic’’ growth
direction of their derivatives may form the fundamental basis of
cancer morphology, which is used ultimately for the histopatho-
logical classification of malignant tumours.
Our observations emphasizes the necessity to consider the
histoanatomic distribution of LGR5
+ cells in tissue based studies,
since the tumour biological effect is clearly related to their spatial
distribution. This is mostly ignored by current studies, running the
risk of misinterpreting obtained results, leading to questionable
conclusions. Our hitherto unreported finding in gastric carcinoma
indicates that especially TMA are not applicable to study the
tumour biological significance of LGR5.
Nevertheless, our findings are in line with current studies,
identifying LGR5 expressing cells as the cells of origin in intestinal
tumours [39]. LGR5 as an optional Wnt coreceptor, is assumed to
mediate the enhancement of Wnt signals by binding soluble R-
spondin proteins [40,41], therefore playing a role in tumour
growth and metastasis [13,42,43]. However, Walker and col-
leagues reported that LGR5 suppression in colorectal cancer cell
lines induced increased invasion, growth and enhanced tumour-
igenicity. They conclude that LGR5 may be important in
restricting stem cells to their niche and loss of LGR5 may
contribute to the invasive phenotype of colorectal carcinoma [16].
In addition to that, our findings now implicate that LGR5
+ cells
and hence the number of stem cells increases and that the stem cell
niche re-allocates during carcinogenesis, i.e. to the luminal surface,
tumour centre and invasion front. LGR5
+ cells lose their
restriction to the stem cell niche of the non-neoplastic mucosa.
These observations are supported by Takeda et al. [26]. Notably
the LGR5 expression at the tumour centre and the invasion front
correlated with tumour growth and nodal spread.
A problem associated with characterization of CSC of solid
cancer is their separation from the surrounding cell population
[44]. The native tumour microenvironment is likely to have a
profound influence on the tumourigenic process [45], also
contributing to the maintenance of the stemness of stem cells
[40]. Even the use of tumour cell lines carries the risk of providing
misleading results.
In conclusion, we provide evidence for an increase of LGR5
+
putative stem cells during gastric tumourigenesis and that the
reallocation of stem cells, e.g. towards the tumour centre and
invasion front, may play a role in the development and progression
of gastric cancer. The spatial histoanatomical distribution of
LGR5
+ cells has to be considered, when their tumour biological
significance is explored in future studies. A more broadly
applicable biomarker that facilitates the identification and
characterization of CSC populations in different tumour sites is
essential, enabling the development of more effective cancer
therapies [46]. LGR5 seems to be a more general marker of
stemness in the gastrointestinal tract, helping to raise novel
hypothesis for the involvement of CSC in tumour development,
progression and growth patterns. However, its tumour biological
function remains obscure and necessitates further investigations.
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Table S1 Primer sequences for polymerase chain
reaction.
(DOC)
Figure S1 Immunocytochemistry of stably transfected
MKN45 cells. LGR5-immunoreactivity in MKN45 gastric
cancer cells stably transfected with LGR5 cDNA (LGR5/
MKN45) (A) compared to control cells, transfected with the
empty vector (B). The lower panel depicts LGR5/MKN45 cells
incubated without the primary antibody (C) or after pre-
incubation of anti-LGR5-antibody with its immunizing blocking
peptide, respectively (D). Original magnifications 6600.
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